{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"submitter":["Walz L"],"pubmed_abstract":["Background Novel coronavirus (SARS-CoV-2) has infected over 17 million. Novel therapies are urgently needed. Janus-kinase (JAK) inhibitors and Type I interferons have emerged as potential antiviral candidates for COVID-19 patients for their proven efficacy against diseases with excessive cytokine release and by their ability to promote viral clearance in past coronaviruses, respectively. We conducted a systemic review and meta-analysis to evaluate role of these therapies in COVID-19 patients. Methods MEDLINE and MedRxiv were searched until July 30th, 2020, including studies that compared treatment outcomes of humans treated with JAK-inhibitor or Type I interferon against controls. Inclusion necessitated data with clear risk estimates or those that permitted back-calculation. Results We sea"],"journal":["medRxiv : the preprint server for health sciences"],"pagination":["2020.08.10.20172189"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7430630"],"repository":["biostudies-literature"],"pubmed_title":["Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis."],"pmcid":["PMC7430630"],"pubmed_authors":["Slade MD","Cohen AJ","Rebaza AP","Vanchieri J","Walz L","Dela Cruz CS","Sharma L"],"additional_accession":[]},"is_claimable":false,"name":"Janus Kinase-Inhibitor and Type I Interferon Ability to Produce Favorable Clinical Outcomes in COVID-19 Patients: A Systematic Review and Meta-Analysis.","description":"Background Novel coronavirus (SARS-CoV-2) has infected over 17 million. Novel therapies are urgently needed. Janus-kinase (JAK) inhibitors and Type I interferons have emerged as potential antiviral candidates for COVID-19 patients for their proven efficacy against diseases with excessive cytokine release and by their ability to promote viral clearance in past coronaviruses, respectively. We conducted a systemic review and meta-analysis to evaluate role of these therapies in COVID-19 patients. Methods MEDLINE and MedRxiv were searched until July 30th, 2020, including studies that compared treatment outcomes of humans treated with JAK-inhibitor or Type I interferon against controls. Inclusion necessitated data with clear risk estimates or those that permitted back-calculation. Results We sea","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2025-04-25T19:41:08.524Z","creation":"2020-08-23T07:07:36Z"},"accession":"S-EPMC7430630","cross_references":{"pubmed":["32817985"],"doi":["10.1101/2020.08.10.20172189"]}}